Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C.

Abstract

HepatologyVolume 36, Issue 4 p. 1022-1022 CorrespondenceFree Access Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C Yuki Terui M.D., Yuki Terui M.D. Second Department of Internal Medicine, Yamagata University School of Medicine, Yamagata, JapanSearch for more papers by this authorTakafumi Saito M.D., Takafumi Saito M.D. Second Department of Internal Medicine, Yamagata University School of Medicine, Yamagata, JapanSearch for more papers by this authorHisayoshi Watanabe M.D., Hisayoshi Watanabe M.D. Second Department of Internal Medicine, Yamagata University School of Medicine, Yamagata, JapanSearch for more papers by this authorHitoshi Togashi M.D., Hitoshi Togashi M.D. Second Department of Internal Medicine, Yamagata University School of Medicine, Yamagata, JapanSearch for more papers by this authorSumio Kawata M.D., Sumio Kawata M.D. Second Department of Internal Medicine, Yamagata University School of Medicine, Yamagata, JapanSearch for more papers by this authorYoshihiro Kamada M.D., Yoshihiro Kamada M.D. Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Osaka, JapanSearch for more papers by this authorShigeru Sakuta M.D., Shigeru Sakuta M.D. Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Osaka, JapanSearch for more papers by this author Yuki Terui M.D., Yuki Terui M.D. Second Department of Internal Medicine, Yamagata University School of Medicine, Yamagata, JapanSearch for more papers by this authorTakafumi Saito M.D., Takafumi Saito M.D. Second Department of Internal Medicine, Yamagata University School of Medicine, Yamagata, JapanSearch for more papers by this authorHisayoshi Watanabe M.D., Hisayoshi Watanabe M.D. Second Department of Internal Medicine, Yamagata University School of Medicine, Yamagata, JapanSearch for more papers by this authorHitoshi Togashi M.D., Hitoshi Togashi M.D. Second Department of Internal Medicine, Yamagata University School of Medicine, Yamagata, JapanSearch for more papers by this authorSumio Kawata M.D., Sumio Kawata M.D. Second Department of Internal Medicine, Yamagata University School of Medicine, Yamagata, JapanSearch for more papers by this authorYoshihiro Kamada M.D., Yoshihiro Kamada M.D. Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Osaka, JapanSearch for more papers by this authorShigeru Sakuta M.D., Shigeru Sakuta M.D. Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Osaka, JapanSearch for more papers by this author First published: 30 December 2003 https://doi.org/10.1053/jhep.2002.32679Citations: 76AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1 Bataller R, Gines P, Nicolas JM, Gorbig MN, Garcia-Ramallo E, Gasull X, Bosch J, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000; 118: 1149– 1156.MEDLINE 2 Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Kishida H, et al. Angiotensin II type 1 receptor interaction is a major regulation for liver fibrosis development in rats. Hepatology 2001; 34: 745– 750.MEDLINE 3 Frei A, Zimmermann A, Weigand K. The N-terminal propeptide of collagen type III in serum reflects activity and degree of fibrosis in patients with chronic liver disease. Hepatology 1984; 4: 830– 834.MEDLINE 4 Tsushima H, Kawata S, Tamaru S, Ito N, Shirai Y, Kiso S, Doi Y, et al. Reduced plasma transforming growth factor-β1 levels in patients with chronic hepatitis C after interferon-α therapy: association with regression of hepatic fibrosis. J Hepatol 1999; 30: 1– 7.MEDLINE 5 Schneider AW, Falk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999; 29: 334– 339.MEDLINE 6 Gonzalez-Abraldes J, Albillos A, Banares R, Arbol LRD, Moitinho E, Rodriqueez C, Gonzalez M, et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001; 121: 382– 388.MEDLINE 7 Schepke M, Werner EVA, Biecker E, Schiedermaier P, Heller J, Neef M, Stoffel-Wagner B, et al. Hemodynamic effects of the angiotensin II receptor antagonist irbestatin in patients with cirrhosis and portal hypertension. Gastroenterology 2001; 121: 389– 395.MEDLINE 8 Schuppan D, Hahn EG. Interleukin 10: the magic bullet for liver fibrosis. Gastroenterology 2000; 119: 1412– 1413.MEDLINE 9 Takano S, Ito Y, Yokosuka O, Ohto M, Uchiumi K, Hirota K, Omata M. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994; 20: 558– 564.MEDLINE 10 Bonkovsky HL. Therapy of hepatitis C: other options. Hepatology 1997; 26(Suppl 1): 143S– 151S.MEDLINE Citing Literature Volume36, Issue4October 2002Pages 1022-1022 ReferencesRelatedInformation